Telix Stock And Two Fast Growing ASX Shares With High Insider Ownership

With inflation trends diverging across regions, energy costs pressuring some economies, and central banks weighing their next moves, growth that is both resilient and well aligned with management confidence is getting more attention. That is where fast growing stocks with high insider ownership come in. This screener focuses on companies where growth expectations from analysts sit alongside meaningful skin in the game from insiders. That combination can help you focus on businesses where leadership is strongly aligned with shareholders. In this article you will see three of the best stocks from this screener to consider for further research.

Predictive Discovery (ASX:PDI)

Overview: Predictive Discovery is a West Africa focused gold company that is developing the large scale Bankan Gold project in Guinea while operating two producing mines in the region. The business aims to turn its resource base into a multi mine production platform from its base in South Perth, Australia.

Market Cap: A$3.3b

Predictive Discovery offers a mix of high growth expectations and meaningful execution risk that fits the fast growing stocks with high insider ownership theme. The merger with Robex has created a producer with two operating mines and the Bankan project under development, with recent operating updates pointing to strong throughput and recoveries at Kiniero and a rising group gold output profile. Analysts see very large potential for revenue and earnings by 2029, yet the company only recently reported a net loss and has less than one year of cash runway, which makes future funding and project delivery critical. Add in recent insider selling and past dilution, and you have a stock where the upside story is clear but the margin for error looks tight.

Predictive Discovery’s big growth story and tight cash cushion put every decision under the microscope. Before you decide how that trade off fits your portfolio, review the 2 key rewards and 4 important warning signs (2 are major!)

Mesoblast (ASX:MSB)

Overview: Mesoblast is a Melbourne based biotech company that develops regenerative cell therapies using mesenchymal lineage cells to treat severe inflammatory and cardiovascular conditions, including graft versus host disease, chronic heart failure and chronic low back pain. Its therapies aim to address serious diseases where current treatments often fall short, through partnerships with larger drug companies and specialist healthcare providers.

Operations: Mesoblast currently generates about US$65.4 million from the development and commercialization of its cell technology platform.

Market Cap: A$2.7b

Mesoblast stands out on this screener because it already has Ryoncil, an FDA approved cell therapy for pediatric steroid refractory acute graft versus host disease, while still offering substantial potential from planned label expansions into adult patients and other inflammatory conditions. Analysts expect strong revenue and earnings growth, and the stock is trading below some estimates of fair value, yet the company remains loss making and leans on higher risk external funding. Recent Ryoncil revenue of US$115 million and progress in the chronic low back pain program hint at a broader commercial story, but much still depends on future trial results, reimbursement stability and how management handles dilution risk and executive pay.

Mesoblast’s Ryoncil story is already big, yet the wider inflammatory and chronic pain pipeline could be even more important. Get the fuller picture through the analyst forecasts for Mesoblast to see what might be easy to miss.

Telix Pharmaceuticals (ASX:TLX)

Overview: Telix Pharmaceuticals develops and sells radiopharmaceutical products that help doctors both find and treat cancers, using targeted imaging agents and therapies across prostate, kidney, brain and other solid tumours in markets including the United States, Europe and Asia.

Operations: Telix Pharmaceuticals generates most of its roughly US$804 million revenue from Precision Medicine at US$621.9 million, with additional contributions from Manufacturing Solutions at US$245.1 million and Therapeutics at US$9.3 million, partly offset by inter segment eliminations of US$72.5 million.

Market Cap: A$4.8b

Telix Pharmaceuticals sits at the point where a commercial radiopharmaceutical business meets a high potential cancer therapy pipeline. Illuccix and Gozellix are already bringing in substantial imaging revenue across more than 20 countries, while recent collaborations such as the Regeneron deal and new manufacturing facilities indicate management is working to control more of the value chain. At the same time, investors need to weigh funding risk, an SEC subpoena and the fact that key trials such as ProstACT Global and LUTEON still need to deliver. For investors comfortable with a higher risk profile, the gap between current pricing, analyst expectations and Telix’s expanding theranostic footprint may be an important consideration.

Telix Pharmaceuticals is already turning cancer imaging into real revenue, yet its theranostic pipeline and manufacturing push could be only half the story. Get the analyst forecasts for Telix Pharmaceuticals before one detail reshapes how you see its risk and reward profile.

The three stocks in this article are a starting point. The full Fast Growing Stocks With High Insider Ownership screener highlights 97 more companies with equally interesting growth stories and insider alignment through the Fast Growing Stocks With High Insider Ownership screener. Use Simply Wall St to identify, filter and analyze the catalysts, insider ownership and analyst narratives that matter most so you can focus on your highest conviction ideas.

Take Control of Your Investment Journey

If Mesoblast or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious About What You Might Be Missing?

Fresh ideas do not stay under the radar for long. Spot companies building quiet momentum before the crowd catches on and before prices start flying. Get in early.

• Look for potential opportunities in established brands and infrastructure by scanning the 35 power grid technology and infrastructure stocks while these companies are still relatively under the radar.
• Follow developments in cleaner baseload energy by checking the 88 nuclear energy infrastructure stocks while investor interest is still developing.
• Track the evolution of automation by reviewing the curated 35 robotics and automation stocks while valuations and expectations may still be adjusting.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com